FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380884003> ?p ?o ?g. }

• W4380884003 abstract "Abstract Background Behavioural and Psychological Symptoms of Dementia (BPSD) in people with Alzheimer’s disease (AD) is particularly distressing to patients and carers. There are currently no licensed medications for BPSD, and the current available treatments have limited benefits and greater risk for side effects. There is therefore a considerable unmet clinical need for interventions that are safe, well‐tolerated and effective for treating BPSD in AD. Cannabidiol (CBD), a non‐addictive substance present in cannabis shows promise for treating psychotic and anxiety symptoms in people without dementia and is generally safe and well‐tolerated in elderly. However, its efficacy, safety and tolerability need to be systematically tested in elderly with dementia. We aimed to evaluate acceptability and tolerability of CBD as treatment for BPSD in patients with AD. Methods We are conducting a double‐blind, parallel group, placebo‐controlled pragmatic randomized controlled feasibility trial (EudraCT Number ‐ 2019‐002106‐52) and recruiting AD patients with BPSD within Mental Health for Older Adults services, South London and Maudsley NHS trust, United Kingdom. Half of the participants receive 600 mg of CBD orally once a day over 6 weeks and the other half receive a placebo, in addition to their usual treatment for 6 weeks. Clinical data collected includes measures of cognition, Clinical Dementia Rating for staging, behaviour symptoms on Neuropsychiatric Inventory (NPI), global functioning, Quality of Life for patients and carer’s burden. Tolerability is assessed by self‐report of side‐effects, and side‐effect rating scale. Results Of the participants recruited and randomised so far, there have been no withdrawals or serious adverse events. The study is ongoing and due for completion at the end of April 2022, following which we will have the data to analyse and present the findings at the July 2022 conference. Conclusions CBD has been generally acceptable and safe for people with AD with BPSD. The final analysis and findings related to adverse events, and changes in clinical measures for the groups (CBD treatment versus placebo) including BPSD, cognition etc. will be presented at the conference." @default.
• W4380884003 created "2023-06-17" @default.
• W4380884003 creator A5007545883 @default.
• W4380884003 creator A5040746273 @default.
• W4380884003 creator A5047197191 @default.
• W4380884003 creator A5051934606 @default.
• W4380884003 creator A5056929602 @default.
• W4380884003 creator A5085954902 @default.
• W4380884003 creator A5092183928 @default.
• W4380884003 date "2023-06-01" @default.
• W4380884003 modified "2023-09-27" @default.
• W4380884003 title "Cannabidiol for neuropsychiatric symptoms in Alzheimer’s dementia" @default.
• W4380884003 doi "https://doi.org/10.1002/alz.067170" @default.
• W4380884003 hasPublicationYear "2023" @default.
• W4380884003 type Work @default.
• W4380884003 citedByCount "0" @default.
• W4380884003 crossrefType "journal-article" @default.
• W4380884003 hasAuthorship W4380884003A5007545883 @default.
• W4380884003 hasAuthorship W4380884003A5040746273 @default.
• W4380884003 hasAuthorship W4380884003A5047197191 @default.
• W4380884003 hasAuthorship W4380884003A5051934606 @default.
• W4380884003 hasAuthorship W4380884003A5056929602 @default.
• W4380884003 hasAuthorship W4380884003A5085954902 @default.
• W4380884003 hasAuthorship W4380884003A5092183928 @default.
• W4380884003 hasBestOaLocation W43808840031 @default.
• W4380884003 hasConcept C118552586 @default.
• W4380884003 hasConcept C126322002 @default.
• W4380884003 hasConcept C159110408 @default.
• W4380884003 hasConcept C168563851 @default.
• W4380884003 hasConcept C197934379 @default.
• W4380884003 hasConcept C2778375690 @default.
• W4380884003 hasConcept C2779134260 @default.
• W4380884003 hasConcept C2779483572 @default.
• W4380884003 hasConcept C2779951463 @default.
• W4380884003 hasConcept C535046627 @default.
• W4380884003 hasConcept C558461103 @default.
• W4380884003 hasConcept C71924100 @default.
• W4380884003 hasConceptScore W4380884003C118552586 @default.
• W4380884003 hasConceptScore W4380884003C126322002 @default.
• W4380884003 hasConceptScore W4380884003C159110408 @default.
• W4380884003 hasConceptScore W4380884003C168563851 @default.
• W4380884003 hasConceptScore W4380884003C197934379 @default.
• W4380884003 hasConceptScore W4380884003C2778375690 @default.
• W4380884003 hasConceptScore W4380884003C2779134260 @default.
• W4380884003 hasConceptScore W4380884003C2779483572 @default.
• W4380884003 hasConceptScore W4380884003C2779951463 @default.
• W4380884003 hasConceptScore W4380884003C535046627 @default.
• W4380884003 hasConceptScore W4380884003C558461103 @default.
• W4380884003 hasConceptScore W4380884003C71924100 @default.
• W4380884003 hasIssue "S7" @default.
• W4380884003 hasLocation W43808840031 @default.
• W4380884003 hasOpenAccess W4380884003 @default.
• W4380884003 hasPrimaryLocation W43808840031 @default.
• W4380884003 hasRelatedWork W1556562895 @default.
• W4380884003 hasRelatedWork W2087016115 @default.
• W4380884003 hasRelatedWork W2107697672 @default.
• W4380884003 hasRelatedWork W2160729253 @default.
• W4380884003 hasRelatedWork W2349164817 @default.
• W4380884003 hasRelatedWork W2363981502 @default.
• W4380884003 hasRelatedWork W2442138394 @default.
• W4380884003 hasRelatedWork W3159250744 @default.
• W4380884003 hasRelatedWork W3189762672 @default.
• W4380884003 hasRelatedWork W4256514411 @default.
• W4380884003 hasVolume "19" @default.
• W4380884003 isParatext "false" @default.
• W4380884003 isRetracted "false" @default.
• W4380884003 workType "article" @default.